tetano
Editor, Senior Moderator
Future Cardiol
. 2021 Feb 22.
doi: 10.2217/fca-2020-0237. Online ahead of print.
Fulminant myocarditis: COVID or not COVID? Reinfection or co-infection?
Ramya Yeleti[SUP] 1 2 [/SUP], Maya Guglin[SUP] 3 [/SUP], Kashif Saleem[SUP] 4 [/SUP], Sasikanth V Adigopula[SUP] 5 [/SUP], Anjan Sinha[SUP] 3 [/SUP], Smrity Upadhyay[SUP] 6 [/SUP], Jeffrey E Everett[SUP] 4 [/SUP], Kareem Ballut[SUP] 3 [/SUP], Sarada Uppuluri[SUP] 5 [/SUP], Roopa A Rao[SUP] 3 [/SUP]
Affiliations
Abstract
We describe a unique case of fulminant myocarditis in a patient with presumed SARS-CoV-2 reinfection. Patient had initial infection 4 months backand had COVID-19 antibody at the time of presentation. Endomyocardial biopsy showed lymphocytic myocarditis, that is usually seen in viral myocarditis. The molecular diagnostic testing of the endomyocardial biopsy for cardiotropic viruses was positive for Parvovirus and negative for SARS-CoV-2. Authors highly suspect co-infection of SARS-CoV-2 and Parvovirus, that possibly triggered the immune cascade resulting in fulminant myocarditis. Patient was hemodynamically unstable with ventricular tachycardia and was supported on VA ECMO and Impella CP. There was impressive recovery of left ventricular function within 48 hours, leading to decannulation of VA ECMO in 72 h. This unique case was written by the survivor herself.
Keywords: SARS-CoV-2; VA ECMO; cardiogenic shock; coronavirus disease-19; fulminant myocarditis.
. 2021 Feb 22.
doi: 10.2217/fca-2020-0237. Online ahead of print.
Fulminant myocarditis: COVID or not COVID? Reinfection or co-infection?
Ramya Yeleti[SUP] 1 2 [/SUP], Maya Guglin[SUP] 3 [/SUP], Kashif Saleem[SUP] 4 [/SUP], Sasikanth V Adigopula[SUP] 5 [/SUP], Anjan Sinha[SUP] 3 [/SUP], Smrity Upadhyay[SUP] 6 [/SUP], Jeffrey E Everett[SUP] 4 [/SUP], Kareem Ballut[SUP] 3 [/SUP], Sarada Uppuluri[SUP] 5 [/SUP], Roopa A Rao[SUP] 3 [/SUP]
Affiliations
- PMID: 33615872
- DOI: 10.2217/fca-2020-0237
Abstract
We describe a unique case of fulminant myocarditis in a patient with presumed SARS-CoV-2 reinfection. Patient had initial infection 4 months backand had COVID-19 antibody at the time of presentation. Endomyocardial biopsy showed lymphocytic myocarditis, that is usually seen in viral myocarditis. The molecular diagnostic testing of the endomyocardial biopsy for cardiotropic viruses was positive for Parvovirus and negative for SARS-CoV-2. Authors highly suspect co-infection of SARS-CoV-2 and Parvovirus, that possibly triggered the immune cascade resulting in fulminant myocarditis. Patient was hemodynamically unstable with ventricular tachycardia and was supported on VA ECMO and Impella CP. There was impressive recovery of left ventricular function within 48 hours, leading to decannulation of VA ECMO in 72 h. This unique case was written by the survivor herself.
Keywords: SARS-CoV-2; VA ECMO; cardiogenic shock; coronavirus disease-19; fulminant myocarditis.